HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Church & Dwight Cuts ‘Power’ Brands To Seven While Reporting, Forecasting Bigger Results

Executive Summary

Health, personal and household care product marketer says raising its annual guidance model from 3% organic growth to 4% driven by expectations for international sales growth, a return to volume-driven sales growth and outlook for Hero and TheraBreath brands.

You may also be interested in...

Volume Returns As Church & Dwight Sales Driver With Economic Headwinds Not Ready To Leave

Higher costs and interest rates due to inflation as well as higher credit card debt point toward consumers spending less in areas including health, personal and household care products. C&D is “well-positioned for this trade down” with 40% of its portfolio in value products, says CEO Matthew Farrell.

Church & Dwight Has Growth Hero In Hero Acne Products, Optimism For Broader Sales Stabilization

Reported revenues for January-March up 10.2% to $1.43bn, with around half the growth coming on sales of Hero Mighty Patch acne treatments. Price increases drove Q1 revenue growth across other categories with volume largely flat.

C&D Oral Care Marketing Flows To Professionals Through WaterPik

Church & Dwight acquires Water Pik Inc. for $1bn in a deal that will give the Arm & Hammer marketer access to the dental professional market, expand its oral care device business and stretch international distribution of water flosser products which already have 90% US market share.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts